Bosulif: Uses, Dosage & Side Effects
A tyrosine kinase inhibitor (TKI) targeting the BCR-ABL oncoprotein for treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in adults and children
Bosulif (bosutinib) is a tyrosine kinase inhibitor (TKI) used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It works by blocking the BCR-ABL oncoprotein, which drives the abnormal proliferation of white blood cells characteristic of this cancer. Bosulif is approved for newly diagnosed adults and children aged 6 years and older with chronic-phase CML, as well as for patients previously treated with other TKIs who have not responded adequately or cannot tolerate those treatments. Available as film-coated tablets in 100 mg, 400 mg, and 500 mg strengths, Bosulif is taken once daily with food. Also marketed under generic names including Bosutinib STADA and Bosutinib Teva.
Quick Facts: Bosulif
Key Takeaways
- Bosulif (bosutinib) is a second-generation BCR-ABL tyrosine kinase inhibitor approved for both newly diagnosed and previously treated Philadelphia chromosome-positive chronic myeloid leukemia in adults and children aged 6 and older.
- The most common side effects are gastrointestinal (diarrhea, nausea, vomiting) and liver enzyme elevations; these require regular monitoring, especially during the first three months of treatment.
- Take Bosulif once daily with food to improve absorption; avoid grapefruit and grapefruit juice, and be aware of significant drug interactions with CYP3A4 inhibitors and inducers.
- Serious but less common risks include hepatotoxicity, myelosuppression (low blood counts), fluid retention, cardiac events, QT prolongation, and renal impairment — all requiring ongoing medical supervision.
- Women of childbearing potential must use effective contraception during treatment and for at least one month after the last dose; breastfeeding is contraindicated during therapy.
What Is Bosulif and What Is It Used For?
Bosulif contains the active substance bosutinib, a potent and selective dual Src/ABL tyrosine kinase inhibitor developed for the treatment of chronic myeloid leukemia (CML). CML is a type of blood cancer that originates in the bone marrow and is characterized by the overproduction of a specific type of white blood cell called granulocytes. In the vast majority of CML cases, the underlying cause is a genetic abnormality known as the Philadelphia chromosome, which results from a reciprocal translocation between chromosomes 9 and 22 — written as t(9;22)(q34;q11). This translocation creates the BCR-ABL fusion gene, which encodes a constitutively active tyrosine kinase that drives the uncontrolled proliferation of leukemia cells.
Bosutinib works by binding to the ATP-binding site of the BCR-ABL kinase, thereby blocking its enzymatic activity and interrupting the downstream signaling pathways that promote cell survival and proliferation. Unlike first-generation TKIs such as imatinib, bosutinib also inhibits members of the Src family of kinases, which may contribute to leukemia cell survival through BCR-ABL-independent pathways. This dual inhibition profile makes bosutinib active against many BCR-ABL mutations that confer resistance to other TKIs, although it is not effective against the T315I mutation.
Bosulif is approved by the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and numerous other regulatory authorities worldwide for the following indications:
- Newly diagnosed chronic-phase Ph+ CML in adults: Bosulif is used as first-line treatment at a dose of 400 mg once daily. The pivotal BFORE trial demonstrated that bosutinib achieved significantly higher rates of major molecular response (MMR) at 12 months compared with imatinib (47.2% vs. 36.9%), establishing its role as a first-line treatment option.
- Newly diagnosed chronic-phase Ph+ CML in children aged 6 years and older: Bosulif is approved for pediatric patients based on pharmacokinetic modeling and clinical data, with dosing based on body surface area (BSA) at 300 mg/m² once daily.
- Chronic-phase, accelerated-phase, or blast-phase Ph+ CML in adults previously treated with one or more TKIs: For patients who have not responded to or cannot tolerate prior therapy (e.g., imatinib, dasatinib, or nilotinib), Bosulif is used at a dose of 500 mg once daily.
- Previously treated Ph+ CML in children aged 6 years and older: Pediatric patients resistant to or intolerant of prior TKI therapy receive bosutinib at 400 mg/m² once daily, based on BSA-adjusted dosing.
CML progresses through three clinical phases. The chronic phase is the earliest and most treatable stage, in which the disease is generally well controlled with TKI therapy. The accelerated phase is an intermediate stage characterized by increasing blast counts and additional genetic abnormalities, signaling disease progression. The blast crisis (or blast phase) is the most advanced and aggressive stage, resembling acute leukemia, with very high blast counts and poor prognosis. Bosulif is used across all three phases, though its primary role is in chronic-phase disease.
In patients with Ph+ CML, a DNA change creates the BCR-ABL fusion protein, which acts as a permanently switched-on signal telling the body to produce too many white blood cells (granulocytes). Bosulif blocks this signal by inhibiting the BCR-ABL tyrosine kinase, thereby stopping the overproduction of these abnormal cells and helping restore normal blood cell production. This targeted mechanism means Bosulif acts primarily on cancer cells while having less impact on normal cells, though some side effects do occur.
What Should You Know Before Taking Bosulif?
Contraindications
There are specific situations in which Bosulif must not be used. Understanding these absolute contraindications is essential before starting treatment.
- Hypersensitivity: Do not take Bosulif if you are allergic to bosutinib or any of the other ingredients in the product (microcrystalline cellulose, croscarmellose sodium, poloxamer 188, povidone, or magnesium stearate).
- Severe hepatic impairment: Bosulif must not be used if your doctor has determined that your liver is significantly damaged and not functioning properly. Bosutinib is extensively metabolized by the liver, and impaired hepatic function can lead to dangerously elevated drug levels.
Warnings and Precautions
Bosulif can cause serious liver damage (hepatotoxicity). Your doctor will perform blood tests to check liver function before starting treatment, regularly during the first three months, and whenever clinically indicated. Symptoms to watch for include yellowing of the eyes or skin (jaundice), dark urine, pain in the upper right abdomen, itching, or fever. Report any of these symptoms to your doctor immediately.
Before and during treatment with Bosulif, inform your doctor if any of the following apply to you:
- Liver problems: If you have or have had any liver disease, including hepatitis of any type, your doctor will monitor your liver function closely. Bosulif can affect liver enzymes and may worsen pre-existing liver conditions. Blood tests will be performed before treatment, at least monthly during the first three months, and periodically thereafter.
- Gastrointestinal issues (diarrhea, vomiting): Diarrhea is one of the most common side effects of Bosulif. Your doctor may prescribe antidiarrheal medications or fluids to manage symptoms. In severe cases, the dose may be reduced, treatment temporarily interrupted, or permanently discontinued. Ask your doctor whether any anti-nausea medications you are taking alongside Bosulif could increase the risk of heart rhythm disturbances.
- Bleeding problems: Bosulif can reduce the body’s ability to form blood clots. Your doctor will check your blood counts weekly during the first month, then monthly. Report any unusual bleeding or bruising immediately.
- Infections: Bosulif can lower your white blood cell count, reducing your body’s ability to fight infections. Report symptoms such as fever, burning sensation when urinating, new or worsening cough, or unexplained sore throat to your doctor.
- Fluid retention: Bosulif may cause fluid accumulation, presenting as swollen ankles, feet, or legs, difficulty breathing, chest pain, or cough. These may indicate fluid around the lungs (pleural effusion) or heart (pericardial effusion). Your doctor will monitor you for signs of fluid retention throughout treatment.
- Heart problems: Inform your doctor if you have heart failure, reduced blood flow to the heart (ischemic heart disease), or any other cardiac condition. Seek immediate medical attention if you experience shortness of breath, weight gain, chest pain, or swelling of the hands, ankles, or feet.
- Heart rhythm disturbances (QT prolongation): Bosulif may affect the electrical activity of the heart, causing a condition known as QT prolongation. This risk is particularly important if you have frequent or prolonged diarrhea, as electrolyte imbalances can worsen this effect. Your doctor will perform an electrocardiogram (ECG) before starting treatment and will monitor your potassium and magnesium levels, correcting any deficiencies.
- Kidney problems: Report changes in urination frequency, volume, or color to your doctor. Kidney function will be assessed before treatment begins and monitored regularly throughout therapy.
- Hepatitis B reactivation: If you have ever had hepatitis B, Bosulif may cause reactivation of the virus, which can be life-threatening. Your doctor will test for hepatitis B before starting treatment and monitor you closely during therapy and for several months after discontinuation.
- Pancreatic problems: If you develop severe abdominal pain or discomfort, and blood tests show elevated lipase levels, your doctor may interrupt treatment and investigate for pancreatitis.
- Severe skin reactions: Serious skin reactions, including erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported. If you develop painful red or purple rashes that spread, blisters, or mucosal lesions (in the mouth or on the lips), treatment will be permanently discontinued.
- Tumor lysis syndrome: In patients with very advanced disease, the rapid destruction of cancer cells can release large amounts of waste products into the blood, potentially causing kidney failure and heart problems within 48 hours of starting Bosulif. Your doctor will ensure adequate hydration and may give preventive medications. Uric acid levels will be checked before treatment begins.
Treatment with bosutinib may increase your sensitivity to sunlight and UV radiation. It is important to protect exposed skin by wearing protective clothing and using a sunscreen with a high SPF during treatment.
Patients of Asian descent may have an increased risk of experiencing side effects with Bosulif. Your doctor will monitor you particularly carefully for serious adverse events, especially when the dose is increased.
Pregnancy and Breastfeeding
Bosulif should not be used during pregnancy unless it is absolutely necessary, as it may cause harm to the developing baby. Animal studies have indicated potential reproductive toxicity. Women of childbearing potential must use effective contraception during treatment and for at least one month after the last dose. It is important to note that vomiting and diarrhea, which are common side effects of Bosulif, may reduce the effectiveness of oral contraceptive pills.
Men considering treatment with Bosulif should be aware that the medication may affect fertility. Sperm preservation (cryopreservation) should be discussed with your doctor before starting therapy.
Breastfeeding must be avoided during treatment with Bosulif, as the drug may pass into breast milk and could harm the nursing infant. Discuss alternative feeding options with your healthcare provider.
Driving and operating machinery: If you experience dizziness, blurred vision, or unusual tiredness while taking Bosulif, you should not drive or operate machinery until these effects have resolved.
How Does Bosulif Interact with Other Drugs?
Bosutinib is primarily metabolized by the cytochrome P450 enzyme CYP3A4 in the liver. This means that other medications that affect CYP3A4 activity can significantly alter bosutinib levels in the blood, either increasing the risk of side effects or reducing the drug’s therapeutic effectiveness. Additionally, bosutinib absorption is affected by gastric pH, making it sensitive to acid-reducing medications. It is critical to inform your doctor about all medications you are taking, including prescription drugs, over-the-counter medicines, vitamins, and herbal supplements.
Major Interactions — Drugs That Increase Bosutinib Levels
The following medications are strong or moderate CYP3A4 inhibitors that can significantly increase bosutinib concentrations in the blood, raising the risk of serious side effects. Your doctor may need to reduce your Bosulif dose or choose an alternative medication:
| Drug | Category | Clinical Significance |
|---|---|---|
| Ketoconazole, Itraconazole, Voriconazole, Posaconazole, Fluconazole | Antifungals | Major — can significantly increase bosutinib exposure |
| Clarithromycin, Telithromycin, Erythromycin, Ciprofloxacin | Antibiotics | Major — dose adjustment may be required |
| Ritonavir, Lopinavir, Indinavir, Nelfinavir, Saquinavir, Atazanavir, Darunavir | HIV Protease Inhibitors | Major — strong CYP3A4 inhibition |
| Diltiazem, Verapamil, Mibefradil | Calcium Channel Blockers | Moderate — monitor closely |
| Imatinib, Crizotinib | Kinase Inhibitors | Moderate — concurrent use may increase toxicity |
| Nefazodone | Antidepressant | Major — strong CYP3A4 inhibition |
| Aprepitant | Antiemetic | Moderate — may increase bosutinib levels |
| Boceprevir, Telaprevir | Hepatitis C Antivirals | Major — strong CYP3A4 inhibition |
Drugs That Decrease Bosutinib Effectiveness
The following medications are CYP3A4 inducers that can significantly reduce bosutinib levels in the blood, potentially making Bosulif less effective against CML. These should be avoided during treatment if possible:
| Drug | Category | Clinical Significance |
|---|---|---|
| Rifampicin | Anti-tuberculosis | Major — reduces bosutinib exposure by up to 6-fold |
| Phenytoin, Carbamazepine | Antiepileptics | Major — strong CYP3A4 induction |
| St. John’s Wort (Hypericum perforatum) | Herbal Supplement | Major — must be avoided during treatment |
| Bosentan | Pulmonary Hypertension | Moderate — may reduce bosutinib levels |
| Efavirenz, Etravirine | HIV Antivirals (NNRTIs) | Moderate to Major — avoid if possible |
| Nafcillin | Antibiotic | Moderate — CYP3A4 induction |
| Modafinil | Wakefulness Agent | Moderate — may reduce bosutinib levels |
QT-Prolonging Drugs
The following medications can affect heart rhythm and should be used with caution when taken alongside Bosulif, as the combination may increase the risk of serious cardiac arrhythmias:
- Cardiac medications: Amiodarone, disopyramide, procainamide, quinidine, sotalol
- Antimalarials: Chloroquine, halofantrine
- Antibiotics: Clarithromycin, moxifloxacin
- Antipsychotics: Haloperidol
- Antiemetics: Domperidone
- Pain medications: Methadone
Acid-Reducing Medications
Proton pump inhibitors (PPIs) such as omeprazole, esomeprazole, and lansoprazole should be used with caution during Bosulif treatment because they raise gastric pH and can significantly reduce bosutinib absorption. If acid suppression is needed, your doctor may consider short-acting antacids as an alternative. If you must take both Bosulif and an antacid, separate the doses as much as possible — for example, take Bosulif in the morning and the antacid in the evening.
Do not consume grapefruit or grapefruit juice while taking Bosulif. Grapefruit inhibits CYP3A4 in the gut wall, which can increase bosutinib absorption and blood levels, raising the risk of serious side effects.
What Is the Correct Dosage of Bosulif?
Bosulif should only be prescribed by physicians experienced in the treatment of leukemia. The dosage depends on whether you are newly diagnosed or have been previously treated, as well as your age and body size. Always take Bosulif exactly as your doctor has instructed. Take the tablet(s) once daily with food, swallowing them whole with water.
Adults
Newly Diagnosed Chronic-Phase CML
The recommended starting dose is 400 mg once daily taken with food. Your doctor may increase or decrease the dose depending on your response and how well you tolerate the medication.
Previously Treated CML (Resistant/Intolerant)
The recommended starting dose is 500 mg once daily taken with food. This higher dose applies to patients in chronic phase, accelerated phase, or blast phase whose previous TKI treatment has failed or who could not tolerate it.
Children and Adolescents (6 Years and Older)
Pediatric dosing is calculated based on body surface area (BSA) in square meters. The following table shows the recommended doses. Different tablet strengths (and hard capsules, where available) can be combined to achieve the prescribed dose.
| Body Surface Area | Newly Diagnosed | Resistant/Intolerant |
|---|---|---|
| 0.55–< 0.63 m² | 200 mg | 250 mg |
| 0.63–< 0.75 m² | 200 mg | 300 mg |
| 0.75–< 0.9 m² | 250 mg | 350 mg |
| 0.9–< 1.1 m² | 300 mg | 400 mg |
| ≥ 1.1 m² | 400 mg* | 500 mg* |
* Maximum starting dose (equivalent to the adult starting dose for the respective indication).
Bosulif is not recommended for children under 6 years of age and has not been studied in children under 1 year.
Elderly Patients
No specific dose adjustment is required based on age alone. However, elderly patients may be more susceptible to certain side effects, particularly hepatotoxicity, fluid retention, and cardiac events. Your doctor will monitor you closely and adjust the dose as needed based on your individual response and tolerability.
Missed Dose
If you forget to take your dose and it has been less than 12 hours since your scheduled time, take the missed dose as soon as you remember. If it has been more than 12 hours, skip the missed dose and take your next dose at the usual time the following day. Do not take a double dose to compensate for a missed tablet.
Overdose
If you accidentally take more Bosulif tablets than prescribed or a higher dose than recommended, contact your doctor or emergency services immediately. Show them the package or this information if possible. You may need medical treatment. There is no specific antidote for bosutinib overdose, and treatment is supportive based on the symptoms observed.
Do not stop taking Bosulif unless your doctor tells you to. Discontinuing treatment without medical supervision may lead to disease progression. If you feel that you no longer need the medication or if you are having difficulty taking it as prescribed, contact your doctor to discuss your options.
What Are the Side Effects of Bosulif?
Like all medicines, Bosulif can cause side effects, although not everybody gets them. Some side effects can be serious and require immediate medical attention. The frequency categories below are based on clinical trial data and post-marketing surveillance reports.
Serious Side Effects — Contact Your Doctor Immediately
Very Common
May affect more than 1 in 10 people
- Decreased platelet count (thrombocytopenia) — may cause abnormal bleeding or easy bruising
- Decreased red blood cell count (anemia) — may cause fatigue, pallor, and shortness of breath
- Decreased neutrophil count (neutropenia) — increases susceptibility to infections
- Fluid accumulation around the lungs (pleural effusion) — may cause breathlessness and chest discomfort
Common
May affect up to 1 in 10 people
- Low white blood cell count (leukopenia)
- Gastrointestinal bleeding — blood in vomit, stool, or urine; black tarry stools
- Chest pain
- Liver toxicity (hepatotoxicity) — jaundice, dark urine, upper abdominal pain, itching
- Heart failure — breathlessness, swelling, fatigue
- Reduced blood flow to the heart (cardiac ischemia)
- Lung infection (pneumonia)
- Abnormal heart rhythm (QT prolongation)
- High blood pressure (hypertension)
- High potassium levels (hyperkalemia)
- Kidney failure or impairment
- Fluid around the heart (pericardial effusion)
- Allergic reaction (drug hypersensitivity)
- Pulmonary hypertension
- Acute pancreatitis
Uncommon
May affect up to 1 in 100 people
- Febrile neutropenia — fever with very low white blood cell count
- Liver damage
- Life-threatening allergic reaction (anaphylactic shock)
- Abnormal fluid accumulation in the lungs (acute pulmonary edema)
- Drug rash, exfoliative dermatitis (peeling skin)
- Inflammation of the membrane around the heart (pericarditis)
- Severe decrease in granulocytes (granulocytopenia)
- Erythema multiforme (severe skin condition)
- Tumor lysis syndrome (TLS) — rapid cell death causing kidney and heart problems
- Respiratory failure
- Cutaneous vasculitis — inflammation of blood vessels in the skin
Not Known
Frequency cannot be estimated from available data
- Stevens-Johnson syndrome / toxic epidermal necrolysis — severe, potentially life-threatening skin reactions
- Interstitial lung disease — scarring of the lungs causing cough and breathlessness
- Hepatitis B reactivation — in patients with prior hepatitis B infection
Other Side Effects
Very Common
May affect more than 1 in 10 people
- Diarrhea, vomiting, abdominal pain, nausea
- Fever (pyrexia), swollen hands, feet, or face (edema), fatigue, weakness
- Upper respiratory tract infection, nasopharyngitis (inflammation of nose and throat)
- Elevated liver enzymes (ALT, AST) and/or pancreatic enzymes (lipase)
- Elevated blood creatinine (kidney function marker)
- Decreased appetite
- Joint pain (arthralgia), back pain
- Headache
- Rash (which may be itchy and/or widespread)
- Cough, shortness of breath (dyspnea)
- Dizziness
Common
May affect up to 1 in 10 people
- Stomach inflammation (gastritis), pain
- Influenza, bronchitis
- Elevated bilirubin, GGT, amylase, or creatine phosphokinase in blood tests
- Low phosphorus levels (hypophosphatemia), dehydration
- Muscle pain (myalgia)
- Altered taste (dysgeusia)
- Ringing in the ears (tinnitus)
- Hives (urticaria), acne
- Photosensitivity reactions (increased sensitivity to sunlight)
- Itching (pruritus)
Reporting suspected side effects after a medicine has been authorized is important to allow continuous monitoring of its benefit-risk balance. Healthcare professionals and patients are encouraged to report any suspected adverse reactions through their national pharmacovigilance reporting system, such as the FDA MedWatch program (US), the Yellow Card Scheme (UK), or the EMA EudraVigilance system (EU).
How Should You Store Bosulif?
Keep Bosulif out of the sight and reach of children at all times. Store the tablets in their original blister packaging to protect them from moisture and light. No special temperature storage conditions are required for this medicine — normal room temperature is suitable.
Do not use Bosulif after the expiry date stated on the blister pack and carton after “EXP.” The expiry date refers to the last day of the stated month. Do not use this medicine if the packaging is damaged or shows signs of tampering.
Do not dispose of medicines in wastewater or household waste. Ask your pharmacist how to properly dispose of medicines that are no longer needed. These measures help protect the environment and prevent accidental exposure.
What Does Bosulif Contain?
The active substance in Bosulif is bosutinib (present as bosutinib monohydrate). The tablets are available in three strengths:
- Bosulif 100 mg: Each film-coated tablet contains 100 mg bosutinib. Yellow, oval, biconvex tablets with “Pfizer” debossed on one side and “100” on the other.
- Bosulif 400 mg: Each film-coated tablet contains 400 mg bosutinib. Orange, oval, biconvex tablets with “Pfizer” debossed on one side and “400” on the other.
- Bosulif 500 mg: Each film-coated tablet contains 500 mg bosutinib. Red, oval, biconvex tablets with “Pfizer” debossed on one side and “500” on the other.
Inactive ingredients (excipients): Microcrystalline cellulose (E460), croscarmellose sodium (E468), poloxamer 188, povidone (E1201), and magnesium stearate (E470b). The film coating contains polyvinyl alcohol, titanium dioxide (E171), macrogol 3350, talc (E553b), and yellow iron oxide (E172, in 100 mg and 400 mg tablets) or red iron oxide (E172, in 400 mg and 500 mg tablets).
Sodium content: This medicine contains less than 1 mmol (23 mg) sodium per film-coated tablet, meaning it is essentially sodium-free.
Pack sizes: Bosulif tablets come in blister packs of 14 or 15 film-coated tablets. Each carton contains 28, 30, or 112 tablets (for 100 mg) or 28 or 30 tablets (for 400 mg and 500 mg). Not all pack sizes may be marketed in every country.
Marketing authorization holder: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium. Manufacturer: Pfizer Manufacturing Deutschland GmbH, Mooswaldallee 1, 79108 Freiburg Im Breisgau, Germany.
Frequently Asked Questions About Bosulif
Bosulif (bosutinib) is a second-generation tyrosine kinase inhibitor (TKI), while imatinib (Gleevec/Glivec) was the first TKI developed for CML. Bosutinib has a different selectivity profile — it inhibits both the BCR-ABL and Src family kinases, which gives it activity against some BCR-ABL mutations that confer resistance to imatinib. In clinical trials, bosutinib achieved higher rates of major molecular response at 12 months compared with imatinib when used as first-line treatment. However, it has a different side-effect profile, with gastrointestinal effects (especially diarrhea) being more prominent. Your doctor will choose the most appropriate TKI based on your specific disease characteristics, mutation profile, and overall health.
Bosulif is typically taken as a long-term, continuous treatment for CML. Many patients take TKI therapy indefinitely, as stopping treatment can lead to disease recurrence in most cases. However, recent research has shown that some patients who achieve a deep and sustained molecular response (known as a deep molecular response or DMR) for a prolonged period may be eligible for a carefully monitored treatment-free remission (TFR) attempt. This decision should only be made by your hematologist based on regular molecular monitoring results. Never stop taking Bosulif without discussing it with your doctor first.
Diarrhea is one of the most common side effects of Bosulif, particularly during the first few weeks of treatment. If you experience diarrhea, stay well hydrated with clear fluids, avoid greasy or spicy foods, and contact your doctor. Your doctor may prescribe antidiarrheal medication (such as loperamide) and may temporarily reduce or interrupt your Bosulif dose. Severe or prolonged diarrhea can lead to dehydration and electrolyte imbalances, which may worsen other side effects such as QT prolongation. In most patients, diarrhea improves over time as the body adjusts to the medication.
There is no specific contraindication against moderate alcohol consumption while taking Bosulif. However, because bosutinib is metabolized by the liver and can itself cause liver toxicity (hepatotoxicity), alcohol consumption may place additional strain on the liver. It is advisable to discuss alcohol use with your doctor, who can provide personalized guidance based on your liver function test results. If your liver enzymes are elevated, your doctor will likely recommend avoiding alcohol entirely.
Yes, generic versions of bosutinib are available in some markets. Approved generic products include Bosutinib STADA and Bosutinib Teva, among others. Generic medications contain the same active ingredient at the same strength and are required to meet the same regulatory standards for quality, safety, and efficacy as the original brand-name product. Your doctor or pharmacist can advise you on whether a generic version is available and appropriate for you. Always ensure any switch between brand and generic is discussed with your healthcare team.
No, Bosulif (bosutinib) is not effective against the T315I BCR-ABL mutation, also known as the “gatekeeper mutation.” This mutation confers resistance to most first- and second-generation TKIs, including imatinib, dasatinib, nilotinib, and bosutinib. The only approved TKI that is effective against the T315I mutation is ponatinib (Iclusig). If your doctor detects a T315I mutation through molecular testing, they will likely recommend switching to ponatinib or considering other treatment options such as asciminib or stem cell transplantation.
References
This article is based on the following peer-reviewed sources, international guidelines, and regulatory documents:
- European Medicines Agency (EMA). Bosulif (bosutinib) — Summary of Product Characteristics (SmPC). Last updated 2025. Available at: ema.europa.eu/en/medicines/human/EPAR/bosulif
- U.S. Food and Drug Administration (FDA). Bosulif (bosutinib) tablets — Prescribing Information. Reference ID: 5243765. Available at: accessdata.fda.gov
- Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol. 2018;36(3):231–237. doi:10.1200/JCO.2017.74.7162
- Brummendorf TH, Cortes JE, Milojkovic D, et al. Bosutinib (BOS) versus imatinib for newly diagnosed chronic phase (CP) chronic myeloid leukemia (CML): final 5-year results from the BFORE trial. Blood. 2022;140(Suppl 1):535–537.
- National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Chronic Myeloid Leukemia. Version 1.2026.
- Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966–984. doi:10.1038/s41375-020-0776-2
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List (2023). Tyrosine kinase inhibitors for CML.
- Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BFORE trial in newly diagnosed chronic phase chronic myeloid leukemia. Leukemia. 2020;34(8):2154–2163. doi:10.1038/s41375-020-0750-z
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians in hematology-oncology, clinical pharmacology, and internal medicine. Our team follows the GRADE evidence framework and adheres to international guidelines from the WHO, EMA, FDA, NCCN, and European LeukemiaNet.
Content developed by physicians with expertise in hematological malignancies and targeted cancer therapies. All claims are supported by peer-reviewed evidence and current regulatory documentation.
Independently reviewed by the iMedic Medical Review Board to ensure accuracy, completeness, and adherence to evidence-based medicine principles. No commercial funding or pharmaceutical sponsorship.
Last medical review: | Next scheduled review:
Conflict of interest: None declared. iMedic operates independently with no commercial funding from pharmaceutical companies.